Mode of Antiviral Action of Silver Nanoparticles Against HIV-1

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2010 Feb 11

PMID 20145735

Citations 261

Authors

Humberto H Lara

Nilda V Ayala-Nunez

Liliana Ixtepan-Turrent

Cristina Rodriguez-Padilla

Affiliations

Soon will be listed here.

Abstract

Background: Silver nanoparticles have proven to exert antiviral activity against HIV-1 at non-cytotoxic concentrations, but the mechanism underlying their HIV-inhibitory activity has not been not fully elucidated. In this study, silver nanoparticles are evaluated to elucidate their mode of antiviral action against HIV-1 using a panel of different in vitro assays.

Results: Our data suggest that silver nanoparticles exert anti-HIV activity at an early stage of viral replication, most likely as a virucidal agent or as an inhibitor of viral entry. Silver nanoparticles bind to gp120 in a manner that prevents CD4-dependent virion binding, fusion, and infectivity, acting as an effective virucidal agent against cell-free virus (laboratory strains, clinical isolates, T and M tropic strains, and resistant strains) and cell-associated virus. Besides, silver nanoparticles inhibit post-entry stages of the HIV-1 life cycle.

Conclusions: These properties make them a broad-spectrum agent not prone to inducing resistance that could be used preventively against a wide variety of circulating HIV-1 strains.

Citing Articles

Staphylococcal Drug Resistance: Mechanisms, Therapies, and Nanoparticle Interventions.

Shao K, Yang Y, Gong X, Chen K, Liao Z, Ojha S Infect Drug Resist. 2025; 18:1007-1033.

PMID: 39990781 PMC: 11847421. DOI: 10.2147/IDR.S510024.

Silver Nanoparticles-Functionalized Textile against SARS-CoV-2: Antiviral Activity of the Capping Oleylamine Molecule.

de Souza T, Rosa A, Constantino-Teles P, Ferreira V, Archanjo B, Soares C ACS Appl Mater Interfaces. 2025; 17(4):5710-5718.

PMID: 39807796 PMC: 11788990. DOI: 10.1021/acsami.4c15289.

Advancements in synthesis, immobilization, characterization, and multifaceted applications of silver nanoparticles: A comprehensive review.

Rabbi M, Haque S, Bedoura S Heliyon. 2025; 10(24):e40931.

PMID: 39759340 PMC: 11700253. DOI: 10.1016/j.heliyon.2024.e40931.

Antimicrobial Feature of Nanoparticles in the Antibiotic Resistance Era: From Mechanism to Application.

Salmani-Zarchi H, Mousavi-Sagharchi S, Sepahdoost N, Ranjbar-Jamalabadi M, Gross J, Jooya H Adv Biomed Res. 2024; 13:113.

PMID: 39717242 PMC: 11665187. DOI: 10.4103/abr.abr_92_24.

Nanotechnology in healthcare, and its safety and environmental risks.

Ma X, Tian Y, Yang R, Wang H, Allahou L, Chang J J Nanobiotechnology. 2024; 22(1):715.

PMID: 39548502 PMC: 11566612. DOI: 10.1186/s12951-024-02901-x.

References

Kim J, Kuk E, Yu K, Kim J, Park S, Lee H . Antimicrobial effects of silver nanoparticles. Nanomedicine. 2007; 3(1):95-101. DOI: 10.1016/j.nano.2006.12.001. View

Elechiguerra J, Burt J, Morones J, Camacho-Bragado A, Gao X, Lara H . Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology. 2005; 3:6. PMC: 1190212. DOI: 10.1186/1477-3155-3-6. View

Al-Jabri A, Alenzi F . Vaccines, virucides and drugs against HIV/AIDS: hopes and optimisms for the future. Open AIDS J. 2009; 3:1-3. PMC: 2644489. DOI: 10.2174/1874613600903010001. View

Zussman A, Lara L, Lara H, Bentwich Z, Borkow G . Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS. 2003; 17(5):653-61. DOI: 10.1097/00002030-200303280-00002. View

Kumar A, Vemula P, Ajayan P, John G . Silver-nanoparticle-embedded antimicrobial paints based on vegetable oil. Nat Mater. 2008; 7(3):236-41. DOI: 10.1038/nmat2099. View

Lekutis C, Olshevsky U, Furman C, Thali M, Sodroski J . Contribution of disulfide bonds in the carboxyl terminus of the human immunodeficiency virus type I gp120 glycoprotein to CD4 binding. J Acquir Immune Defic Syndr (1988). 1992; 5(1):78-81. View

Bhattacharya R, Mukherjee P . Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev. 2008; 60(11):1289-1306. DOI: 10.1016/j.addr.2008.03.013. View

Lawn S, Butera S, Folks T . Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev. 2001; 14(4):753-77, table of contents. PMC: 89002. DOI: 10.1128/CMR.14.4.753-777.2001. View

McDonnell G, Russell A . Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999; 12(1):147-79. PMC: 88911. DOI: 10.1128/CMR.12.1.147. View

10.

Vercauteren J, Deforche K, Theys K, Debruyne M, Duque L, Peres S . The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology. 2008; 5:12. PMC: 2265747. DOI: 10.1186/1742-4690-5-12. View

11.

Taylor P, Ussher A, Burrell R . Impact of heat on nanocrystalline silver dressings. Part I: Chemical and biological properties. Biomaterials. 2005; 26(35):7221-9. DOI: 10.1016/j.biomaterials.2005.05.040. View

12.

Dunn K, Edwards-Jones V . The role of Acticoat with nanocrystalline silver in the management of burns. Burns. 2004; 30 Suppl 1:S1-9. DOI: 10.1016/s0305-4179(04)90000-9. View

13.

Borkow G, Lapidot A . Multi-targeting the entrance door to block HIV-1. Curr Drug Targets Infect Disord. 2005; 5(1):3-15. DOI: 10.2174/1568005053174645. View

14.

Leonard C, Spellman M, Riddle L, Harris R, Thomas J, Gregory T . Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem. 1990; 265(18):10373-82. View

15.

Li Y, Leung P, Yao L, Song Q, Newton E . Antimicrobial effect of surgical masks coated with nanoparticles. J Hosp Infect. 2005; 62(1):58-63. DOI: 10.1016/j.jhin.2005.04.015. View

16.

Spira S, Wainberg M, Loemba H, Turner D, Brenner B . Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother. 2003; 51(2):229-40. DOI: 10.1093/jac/dkg079. View

17.

Morones J, Elechiguerra J, Camacho A, Holt K, Kouri J, Tapia Ramirez J . The bactericidal effect of silver nanoparticles. Nanotechnology. 2010; 16(10):2346-53. DOI: 10.1088/0957-4484/16/10/059. View

18.

O Connor T . Assessment of activity of topical virucidal agents. Methods Mol Med. 2011; 24:207-12. DOI: 10.1385/1-59259-245-7:207. View

19.

Bhol K, Schechter P . Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. Br J Dermatol. 2005; 152(6):1235-42. DOI: 10.1111/j.1365-2133.2005.06575.x. View

20.

Borkow G, Barnard J, Nguyen T, Belmonte A, Wainberg M, Parniak M . Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol. 1997; 71(4):3023-30. PMC: 191431. DOI: 10.1128/JVI.71.4.3023-3030.1997. View